Pfizer bolsters haematology expertise with $5.4bn deal

09-08-2022

Staff Writer

Pfizer bolsters haematology expertise with $5.4bn deal

Molly Woodward / Shutterstock.com

Pharma giant to acquire biopharma firm specialising in sickle cell treatment | Key treatment will be distributed to countries most impacted by the disease.


Pfizer, M&A, mergers and acquisitions, Global Blood Therapeutics, sickle cell disease, Oxbryta, acquisitions

LSIPR